Cannabinoid CB 1 receptors transactivate multiple receptor tyrosine kinases and regulate serine/ threonine kinases to activate ERK in neuronal cells

British Journal of Pharmacology

Volumn 165, Issue 8, 2012, Pages 2497-2511

  Dalton, George D ^a   Howlett, Allyn C ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Cannabinoids; CB 1 receptor; ERK; PTP1B; Receptor tyrosine kinase; Src

Indexed keywords

CANNABINOID 1 RECEPTOR; CYCLIC AMP DEPENDENT PROTEIN KINASE; LIGAND; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOPROTEIN PHOSPHATASE 1; PHOSPHOPROTEIN PHOSPHATASE 2A; PHOSPHOPROTEIN PHOSPHATASE INHIBITOR; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE PHOSPHATASE 1B; PROTEIN TYROSINE PHOSPHATASE SHP 1; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; BENZOXAZINE DERIVATIVE; CANNABINOID; MORPHOLINE DERIVATIVE; NAPHTHALENE DERIVATIVE; PROTEIN KINASE;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ENZYME REGULATION; ENZYME SPECIFICITY; MOUSE; NERVE CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; TRANSACTIVATION; ANIMAL; METABOLISM; PHOSPHORYLATION; TRANSCRIPTION INITIATION; TUMOR CELL LINE;

ANIMALS; BENZOXAZINES; CANNABINOIDS; CELL LINE, TUMOR; MICE; MORPHOLINES; NAPHTHALENES; NEURONS; PHOSPHORYLATION; PROTEIN KINASES; RECEPTOR, CANNABINOID, CB1; TRANSCRIPTIONAL ACTIVATION;

EID: 84859057169     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01455.x     Document Type: Article

References (69)

1. Alexander SPH, Mathie A, Peters JA (2011). Guide to Receptors and Channels (GRAC), 5th Edition. Br J Pharmacol 164 (Suppl. 1): S1-S324.
2. Arabaci G, Yi T, Fu H, Porter ME, Beebe KD, Pei D (2002). alpha-bromoacetophenone derivatives as neutral protein tyrosine phosphatase inhibitors: structure-Activity relationship. Bioorg Med Chem Lett 12: 3047-3050.
3. Belcheva MM, Coscia CJ (2002). Diversity of G protein-coupled receptor signaling pathways to ERK/MAP kinase. Neurosignals 11: 34-44. (Pubitemid 37499848)
4. Belcheva MM, Szucs M, Wang D, Sadee W, Coscia CJ (2001). mu-Opioid receptor-mediated ERK activation involves calmodulin-dependent epidermal growth factor receptor transactivation. J Biol Chem 276: 33847-33853.
5. Berghuis P, Dobszay MB, Wang X, Spano S, Ledda F, Sousa KM et al. (2005). Endocannabinoids regulate interneuron migration and morphogenesis by transactivating the TrkB receptor. Proc Natl Acad Sci U S A 102: 19115-19120. (Pubitemid 43049575)
6. Bisogno T, Sepe N, Melck D, Maurelli S, De Petrocellis L, Di Marzo V (1997). Biosynthesis, release and degradation of the novel endogenous cannabimimetic metabolite 2-arachidonoylglycerol in mouse neuroblastoma cells. Biochem J 322: 671-677. (Pubitemid 27116599)
7. Blum G, Gazit A, Levitzki A (2000). Substrate competitive inhibitors of IGF-1 receptor kinase. Biochemistry 39: 15705-15712. (Pubitemid 32038232)
8. Bouaboula M, Poinot-Chazel C, Bourrie B, Canat X, Calandra B, Rinaldi-Carmona M et al. (1995). Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor CB1. Biochem J 312 (Pt 2):637-641. (Pubitemid 26002235)
9. Bouaboula M, Perrachon S, Milligan L, Canat X, Rinaldi-Carmona M, Portier M et al. (1997). A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1. Evidence for a new model of receptor/ligand interactions. J Biol Chem 272: 22330-22339. (Pubitemid 27382869)
10. Bourdeau A, Dube N, Tremblay ML (2005). Cytoplasmic protein tyrosine phosphatases, regulation and function: the roles of PTP1B and TC-PTP. Curr Opin Cell Biol 17: 203-209. (Pubitemid 40380945)
11. Bouschet T, Perez V, Fernandez C, Bockaert J, Eychene A, Journot L (2003). Stimulation of the ERK pathway by GTP-loaded Rap1 requires the concomitant activation of Ras, protein kinase C, and protein kinase A in neuronal cells. J Biol Chem 278: 4778-4785. (Pubitemid 36800980)
12. Bradford MM (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254.
13. Chen L, Sung SS, Yip ML, Lawrence HR, Ren Y, Guida WC et al. (2006). Discovery of a novel shp2 protein tyrosine phosphatase inhibitor. Mol Pharmacol 70: 562-570. (Pubitemid 44092317)
14. Chen Z, Gibson TB, Robinson F, Silvestro L, Pearson G, Xu B et al. (2001). MAP kinases. Chem Rev 101: 2449-2476. (Pubitemid 35373029)
15. Daigle TL, Kearn CS, Mackie K (2008). Rapid CB1 cannabinoid receptor desensitization defines the time course of ERK1/2 MAP kinase signaling. Neuropharmacology 54: 36-44. (Pubitemid 350299401)
16. Davis MI, Ronesi J, Lovinger DM (2003). A predominant role for inhibition of the adenylate cyclase/protein kinase A pathway in ERK activation by cannabinoid receptor 1 in N1E-115 neuroblastoma cells. J Biol Chem 278: 48973-48980.
17. Dent G, Giembycz MA, Evans PM, Rabe KF, Barnes PJ (1994). Suppression of human eosinophil respiratory burst and cyclic AMP hydrolysis by inhibitors of type IV phosphodiesterase: interaction with the beta adrenoceptor agonist albuterol. J Pharmacol Exp Ther 271: 1167-1174. (Pubitemid 24382617)
18. Derkinderen P, Valjent E, Toutant M, Corvol JC, Enslen H, Ledent C et al. (2003). Regulation of extracellular signal-regulated kinase by cannabinoids in hippocampus. J Neurosci 23: 2371-2382. (Pubitemid 36368926)
19. Dudley DT, Pang L, Decker SJ, Bridges AJ, Saltiel AR (1995). A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc Natl Acad Sci U S A 92: 7686-7689.
20. Galve-Roperh I, Rueda D, Gomez del Pulgar T, Velasco G, Guzman M (2002). Mechanism of extracellular signal-regulated kinase activation by the CB(1) cannabinoid receptor. Mol Pharmacol 62: 1385-1392. (Pubitemid 35403833)
21. Hanke JH, Gardner JP, Dow RL, Changelian PS, Brissette WH, Weringer EJ et al. (1996). Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent T cell activation. J Biol Chem 271: 695-701.
22. Hart S, Fischer OM, Ullrich A (2004). Cannabinoids induce cancer cell proliferation via tumor necrosis factor alpha-converting enzyme (TACE/ADAM17)-mediated transactivation of the epidermal growth factor receptor. Cancer Res 64: 1943-1950. (Pubitemid 38339438)
23. Hawes BE, Luttrell LM, van Biesen T, Lefkowitz RJ (1996). Phosphatidylinositol 3-kinase is an early intermediate in the G beta gamma-mediated mitogen-activated protein kinase signaling pathway. J Biol Chem 271: 12133-12136.
24. Haystead TA, Sim AT, Carling D, Honnor RC, Tsukitani Y, Cohen P et al. (1989). Effects of the tumour promoter okadaic acid on intracellular protein phosphorylation and metabolism. Nature 337: 78-81. (Pubitemid 19022553)
25. Howlett AC (2005). Cannabinoid receptor signaling. Handb Exp Pharmacol 168: 53-79.
26. Howlett AC, Fleming RM (1984). Cannabinoid inhibition of adenylate cyclase. Pharmacology of the response in neuroblastoma cell membranes. Mol Pharmacol 26: 532-538. (Pubitemid 15190717)
27. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA et al. (2002). International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 54: 161-202. (Pubitemid 34575709)
28. Jin W, Brown S, Roche JP, Hsieh C, Celver JP, Kovoor A et al. (1999). Distinct domains of the CB1 cannabinoid receptor mediate desensitization and internalization. J Neurosci 19: 3773-3780. (Pubitemid 29222253)
29. Junttila MR, Li SP, Westermarck J (2008). Phosphatase-mediated crosstalk between MAPK signaling pathways in the regulation of cell survival. FASEB J 22: 954-965. (Pubitemid 351519953)
30. Kase H, Iwahashi K, Nakanishi S, Matsuda Y, Yamada K, Takahashi M et al. (1987). K-252 compounds, novel and potent inhibitors of protein kinase C and cyclic nucleotide-dependent protein kinases. Biochem Biophys Res Commun 142: 436-440. (Pubitemid 17003365)
31. Kikuchi A, Williams LT (1996). Regulation of interaction of ras p21 with RalGDS and Raf-1 by cyclic AMP-dependent protein kinase. J Biol Chem 271: 588-594.
32. Korzh A, Keren O, Gafni M, Bar-Josef H, Sarne Y (2008). Modulation of extracellular signal-regulated kinase (ERK) by opioid and cannabinoid receptors that are expressed in the same cell. Brain Res 1189: 23-32.
33. Kovalenko M, Gazit A, Bohmer A, Rorsman C, Ronnstrand L, Heldin CH et al. (1994). Selective platelet-derived growth factor receptor kinase blockers reverse sis-transformation. Cancer Res 54: 6106-6114. (Pubitemid 24378640)
34. Kyosseva SV (2004). Mitogen-activated protein kinase signaling. Int Rev Neurobiol 59: 201-220.
35. Lehmann DM, Seneviratne AM, Smrcka AV (2008). Small molecule disruption of G protein beta gamma subunit signaling inhibits neutrophil chemotaxis and inflammation. Mol Pharmacol 73: 410-418. (Pubitemid 351159211)
36. Levitzki A, Gazit A (1995). Tyrosine kinase inhibition: an approach to drug development. Science 267: 1782-1788.
37. Lopez-Ilasaca M, Crespo P, Pellici PG, Gutkind JS, Wetzker R (1997). Linkage of G protein-coupled receptors to the MAPK signaling pathway through PI 3-kinase gamma. Science 275: 394-397. (Pubitemid 27051618)
38. Luttrell LM, Hawes BE, van Biesen T, Luttrell DK, Lansing TJ, Lefkowitz RJ (1996). Role of c-Src tyrosine kinase in G protein-coupled receptor- and Gbetagamma subunit-mediated activation of mitogen-activated protein kinases. J Biol Chem 271: 19443-19450. (Pubitemid 26271617)
39. Luttrell LM, Della Rocca GJ, van Biesen T, Luttrell DK, Lefkowitz RJ (1997). Gbetagamma subunits mediate Src-dependent phosphorylation of the epidermal growth factor receptor. A scaffold for G protein-coupled receptor-mediated Ras activation. J Biol Chem 272: 4637-4644. (Pubitemid 27086335)
40. McVey M, Hill J, Howlett A, Klein C (1999). Adenylyl cyclase, a coincidence detector for nitric oxide. J Biol Chem 274: 18887-18892.
41. Mischak H, Seitz T, Janosch P, Eulitz M, Steen H, Schellerer M et al. (1996). Negative regulation of Raf-1 by phosphorylation of serine 621. Mol Cell Biol 16: 5409-5418. (Pubitemid 26315060)
42. Pertwee RG (2006). Cannabinoid pharmacology: the first 66 years. Br J Pharmacol 147 (Suppl. 1): S163-S171.
43. Powis G, Bonjouklian R, Berggren MM, Gallegos A, Abraham R, Ashendel C et al. (1994). Wortmannin, a potent and selective inhibitor of phosphatidylinositol-3-kinase. Cancer Res 54: 2419-2423.
44. Rhee MH, Bayewitch M, Avidor-Reiss T, Levy R, Vogel Z (1998). Cannabinoid receptor activation differentially regulates the various adenylyl cyclase isozymes. J Neurochem 71: 1525-1534. (Pubitemid 28443025)
45. Roskoski R Jr (2005). Src kinase regulation by phosphorylation and dephosphorylation. Biochem Biophys Res Commun 331: 1-14.
46. Roudabush FL, Pierce KL, Maudsley S, Khan KD, Luttrell LM (2000). Transactivation of the EGF receptor mediates IGF-1-stimulated shc phosphorylation and ERK1/2 activation in COS-7 cells. J Biol Chem 275: 22583-22589. (Pubitemid 30621851)
47. Roux PP, Blenis J (2004). ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. Microbiol Mol Biol Rev 68: 320-344. (Pubitemid 38756868)
48. Rubino T, Forlani G, Vigano D, Zippel R, Parolaro D (2004). Modulation of extracellular signal-regulated kinases cascade by chronic delta 9-tetrahydrocannabinol treatment. Mol Cell Neurosci 25: 355-362. (Pubitemid 38366401)
49. Rubino T, Forlani G, Vigano D, Zippel R, Parolaro D (2005). Ras/ERK signalling in cannabinoid tolerance: from behaviour to cellular aspects. J Neurochem 93: 984-991. (Pubitemid 40695757)
50. Rubovitch V, Gafni M, Sarne Y (2004). The involvement of VEGF receptors and MAPK in the cannabinoid potentiation of Ca2+ flux into N18TG2 neuroblastoma cells. Brain Res Mol Brain Res 120: 138-144. (Pubitemid 38115810)
51. Rueda D, Galve-Roperh I, Haro A, Guzman M (2000). The CB(1) cannabinoid receptor is coupled to the activation of c-Jun N-terminal kinase. Mol Pharmacol 58: 814-820.
52. Rueda D, Navarro B, Martinez-Serrano A, Guzman M, Galve-Roperh I (2002). The endocannabinoid anandamide inhibits neuronal progenitor cell differentiation through attenuation of the Rap1/B-Raf/ERK pathway. J Biol Chem 277: 46645-46650. (Pubitemid 35417665)
53. Saito Y, Haendeler J, Hojo Y, Yamamoto K, Berk BC (2001). Receptor heterodimerization: essential mechanism for platelet-derived growth factor-induced epidermal growth factor receptor transactivation. Mol Cell Biol 21: 6387-6394. (Pubitemid 32927407)
54. Santiskulvong C, Rozengurt E (2003). Galardin (GM 6001), a broad-spectrum matrix metalloproteinase inhibitor, blocks bombesin- and LPA-induced EGF receptor transactivation and DNA synthesis in rat-1 cells. Exp Cell Res 290: 437-446. (Pubitemid 37272186)
55. Seamon KB, Padgett W, Daly JW (1981). Forskolin: unique diterpene activator of adenylate cyclase in membranes and in intact cells. Proc Natl Acad Sci U S A 78: 3363-3367. (Pubitemid 11059290)
56. Shushan A, Rojansky N, Laufer N, Klein BY, Shlomai Z, Levitzki R et al. (2004). The AG1478 tyrosine kinase inhibitor is an effective suppressor of leiomyoma cell growth. Hum Reprod 19: 1957-1967. (Pubitemid 39236459)
57. Somani AK, Bignon JS, Mills GB, Siminovitch KA, Branch DR (1997). Src kinase activity is regulated by the SHP-1 protein-tyrosine phosphatase. J Biol Chem 272: 21113-21119. (Pubitemid 27373970)
58. Stephens LR, Eguinoa A, Erdjument-Bromage H, Lui M, Cooke F, Coadwell J et al. (1997). The G beta gamma sensitivity of a PI3K is dependent upon a tightly associated adaptor, p101. Cell 89: 105-114. (Pubitemid 27180590)
59. Sun L, Tran N, Tang F, App H, Hirth P, McMahon G et al. (1998). Synthesis and biological evaluations of 3-substituted indolin-2-ones: a novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases. J Med Chem 41: 2588-2603. (Pubitemid 28321908)
60. Tonini R, Ciardo S, Cerovic M, Rubino T, Parolaro D, Mazzanti M et al. (2006). ERK-dependent modulation of cerebellar synaptic plasticity after chronic Delta9-tetrahydrocannabinol exposure. J Neurosci 26: 5810-5818. (Pubitemid 44315274)
61. Traverse S, Gomez N, Paterson H, Marshall C, Cohen P (1992). Sustained activation of the mitogen-activated protein (MAP) kinase cascade may be required for differentiation of PC12 cells. Comparison of the effects of nerve growth factor and epidermal growth factor. Biochem J 288: 351-355.
62. Valjent E, Pages C, Rogard M, Besson MJ, Maldonado R, Caboche J (2001). Delta 9-tetrahydrocannabinol-induced MAPK/ERK and Elk-1 activation in vivo depends on dopaminergic transmission. Eur J Neurosci 14: 342-352. (Pubitemid 32777639)
63. Van Haastert PJ, Van Driel R, Jastorff B, Baraniak J, Stec WJ, De Wit RJ (1984). Competitive cAMP antagonists for cAMP-receptor proteins. J Biol Chem 259: 10020-10024. (Pubitemid 14067669)
64. Vlahos CJ, Matter WF, Hui KY, Brown RF (1994). A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8- phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem 269: 5241-5248.
65. Vossler MR, Yao H, York RD, Pan MG, Rim CS, Stork PJ (1997). cAMP activates MAP kinase and Elk-1 through a B-Raf- and Rap1-dependent pathway. Cell 89: 73-82. (Pubitemid 27180587)
66. Werry TD, Sexton PM, Christopoulos A (2005). 'Ins and outs' of seven-transmembrane receptor signalling to ERK. Trends Endocrinol Metab 16: 26-33. (Pubitemid 40037724)
67. Wetzker R, Bohmer FD (2003). Transactivation joins multiple tracks to the ERK/MAPK cascade. Nat Rev Mol Cell Biol 4: 651-657. (Pubitemid 36934967)
68. Wiesmann C, Barr KJ, Kung J, Zhu J, Erlanson DA, Shen W et al. (2004). Allosteric inhibition of protein tyrosine phosphatase 1B. Nat Struct Mol Biol 11: 730-737. (Pubitemid 39014498)
69. Zhou B, Wang ZX, Zhao Y, Brautigan DL, Zhang ZY (2002). The specificity of extracellular signal-regulated kinase 2 dephosphorylation by protein phosphatases. J Biol Chem 277: 31818-31825. (Pubitemid 34968988)